UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) 245 First Street, Cambridge, MA 02142 (Address of principal executive offices) (Zip Code) Delaware 20-8756903 (I.R.S. Employer Identification No.) Registrant's telephone ...

Akebia Therapeutics, Inc. (NASDAQ:AKBA) Q3 2022 Results Conference Call November 3, 2022 4:30 PM ET Company Participants Mercedes Carrasco - Senior Director of Corporate Communications John Butler - CEO, President and Director David Spellman - Senior VP, CFO and Treasurer Conference Call Participants Allison Bratzel - Piper Sandler Thomas Yip - H.C. Wainwright Operator Good day and thank you for standing by. Welcome to the Akebia's Third Quarter 2022 Financial Results Conference Call. At this time, all part ...

Akebia Therapeutics Inc. (NASDAQ:AKBA) Q2 2022 Earnings Conference Call August 4, 2022 4:30 PM ET Company Participants Mercedes Carrasco - Senior Director of Corporate Communications John Butler - CEO, President and Director Steve Burke - Senior VP of Research and Development and Chief Medical Officer David Spellman - Senior VP, CFO and Treasurer Conference Call Participants Allison Bratzel - Piper Sandler Operator Hello, and welcome to the Akebia Second Quarter 2022 Financial Results. [Operator Instruction ...

Akebia Therapeutics, Inc. (NASDAQ:AKBA) Q1 2022 Earnings Conference Call May 9, 2022 4:30 PM ET Company Participants Mercedes Carrasco - Director, Corporate Communications John Butler - CEO, President & Director David Spellman - SVP, CFO & Treasurer Conference Call Participants Allison Bratzel - Piper Sandler & Co. Mara Goldstein - Mizuho Securities Antonio Arce - H.C. Wainwright & Co. Rohit Bhasin - Needham Operator Ladies and gentlemen, thank you for standing by, and welcome to the Akebia First Quarter 20 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _to_ Commission File Number 001-36352 AKEBIA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporatio ...

Akebia Therapeutics, Inc. (NASDAQ:AKBA) Q3 2021 Earnings Conference Call November 9, 2021 9:00 AM ET Company Participants Mercedes Carrasco - Director, Corporate Communications John Butler - Chief Executive Officer Dave Spellman - Chief Financial Officer Dell Faulkingham - Chief Commercial Officer Steven Burke - Head of R&D and Chief Medical Officer Conference Call Participants Alli Bratzel - Piper Sandler Alethia Young - Cantor Fitzgerald Eric Joseph - JP Morgan Serge Belanger - Needham and Company Avatar ...